GlassScriptPhysician profile
Karen Ann Johnson
NPI 1063703510
$6,018.71
in general payments reported to CMS, 2019-2025
33 companies · $600 in 2025
The $600 reported for 2025 was more than what 78% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,475 · 2022: $1,509 · 2023: $1,241 · 2024: $1,194 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,034.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,036.83 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $867.74 | 2021-2025 | |
| Lilly USA, LLC | $606.51 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $572.36 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $420.22 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $386.63 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.76 | 2022-2025 | Jardiance, Synjardy |
| Biohaven Pharmaceutical Holding Company LTD. | $205.12 | 2022 | |
| Biotronik INC. | $149.34 | 2023 | Renamic Neo, Rivacor 7 Dr-T, Amvia Edge |
| Esperion Therapeutics, INC. | $144.16 | 2021-2023 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $142.02 | 2021-2024 | Trintellix |
| Abbott Laboratories | $125.14 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Cardiva Medical, INC. | $119.27 | 2023 | Cardiva Vascade 6/7f Vcs |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.99 | 2021-2025 | Xifaxan |
| Amarin Pharma, INC. | $111.67 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $110.60 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $104.53 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $82.54 | 2021-2022 | |
| Globus Medical, INC. | $75.25 | 2025 | Senza |
| Novartis Pharmaceuticals Corporation | $74.56 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $72.96 | 2021-2023 | Xarelto |
| Alk-Abello, INC | $43.87 | 2024 | Ragwitek, Odactra, Grastek |
| Sumitomo Pharma America, INC. | $34.32 | 2024-2025 | Gemtesa |
| Shield Therapeutics INC | $30.22 | 2022-2024 | |
| Exact Sciences Corporation | $28.10 | 2025 | Cologuard Collection Kit |
| Acerus Pharmaceuticals Corporation | $25.75 | 2022 | |
| Boston Scientific Corporation | $22.17 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.18 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $17.71 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.03 | 2021 | |
| Horizon Therapeutics Plc | $14.37 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.20 | 2025 | Keveyis |
| Genentech USA, INC. | $13.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.